Halozyme Therapeutics (HALO) PT Raised to $53 at Piper Sandler; ''25+ Guidance Higher As Wave 3 Launches Take Shape'
Tweet Send to a Friend
Piper Sandler analyst Joseph Catanzaro raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $53.00 (from $52.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
